Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone(02/12/2008) Study Achieves Primary Efficacy Endpoint and Demonstrates Improved Quality of Sleep Labopharm Inc. announced that its recently completed North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001) achieved statistical significance for the primary efficacy endpoint (p ...
Top
